Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's go NRBO > $$$$$
Scooped up the 1.56 shares. Finaly done with shelf placements. At least for now!
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
9:08 am ET November 4, 2022 (Globe Newswire) Print
GlobeNewswireNovember 04, 2022
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 shares of its common stock at a price of $6.67 per share in an underwritten offering. The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million. The offering is expected to close on or about November 8, 2022, subject to the satisfaction of customary closing conditions.
BioAtla intends to use the net proceeds to be received by it in the offering, along with its existing cash and cash equivalents to fund our research and development efforts, including Phase 2 clinical trials and potential commercialization of mecbotamab vedotin (BA3011), Phase 2 clinical trials of ozuriftamab vedotin (BA3021), clinical development of BA3071, preclinical development of several of our other CAB candidates, and for working capital and other general corporate purposes.
Investors in the offering include Acuta Capital Partners, Adage Capital Partners, Cormorant Asset Management, EcoR1 Capital, Janus Henderson Investors, Soleus Capital and Vivo Capital.
J.P. Morgan Securities LLC is acting as sole book-running manager.
A "shelf" registration statement on Form S-3 (File No. 333-262528) relating to the underwritten offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on May 18, 2022. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmorgan.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation, or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BioAtla(R), Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing in the United States, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc., visit www.bioatla.com.
Forward-Looking Statements
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words and include, without limitation, statements regarding the expected gross proceeds from the offering, the timing of completion of the offering and expected use of proceeds. Forward-looking statements are based on BioAtla's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others, uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the completion of the offering on the anticipated terms or at all, and the other risks and uncertainties described in the section titled "Risk Factors" in our Quarterly Report on Form 10-Q filed with the SEC on November 4, 2022, the final prospectus supplement and accompanying prospectus related to the offering and our other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required under applicable law.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
BioAtla Initiated at Market Outperform by JMP Securities
BioAtla Reports Q3 2022 Cash Balance Of $178.1M
In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on BioAtla (BCAB - Research Report), with a price target of $20.00. The company's shares closed yesterday at $6.36.According to TipRanks, He CFA is a 3-star analyst with an average return of 29.7% and a 66.67% success rate. He CFA covers the Healthcare sector, focusing on stocks such as Hookipa Pharma, BioAtla, and LAVA Therapeutics.BioAtla has an analyst consensus of Strong Buy, with a price target consensus of $16.00.
https://www.tipranks.com/news/blurbs/bioatla-bcab-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Musk's focus is now with his private company > Twitter.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidate includes BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin) and BA3071 (Ozuriftabmab vedotin). The Company’s lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL that is protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. It has initiated a Phase I/II dose-escalation trial of BA3071 as monotherapy and in combination with an anti-PD-1 antibody with expansion cohorts to be enrolled upon identification of the recommended dose.
With heavy volume, the placement may close early next week.
Virax Biolabs Group Limited Announces $3.8M Private Placement Agreement
Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 2,330,000 shares of ordinary shares (or ordinary shares equivalents in lieu thereof) at a gross purchase price of $1.65 per share. Additionally, Virax has agreed to issue to the investor unregistered warrants to purchase up to 3,495,000 shares of ordinary shares (the "Ordinary Warrants"). The Ordinary Warrants have an exercise price of $1.73 per share, will become exercisable in six months after their date of issuance and will expire five and a half years from their date of issuance.
There are over 4 million diesel engine tractor trailers in USA. You may want to worry about food and produce getting delivered to your supermarket. Wegmans Supermarket in Northeast USA recently purchased 45 nat gas fueled tractors.
Let's see if Elon Musk considers building nat gas engines and electric truck engines.
LMAO! Very creative!
TRUMP 007 GOLDENHAIR :
$olid day! Later this month, we'll see 52 week high. Let's go TELL !
RSV - Influenza spreading fast and furious in Europe as well as USA. These test kits are in demand.
Virax's Chairman of the Board and Chief Executive Officer, James Foster commented "the major industrialized economies are facing a triple threat this year through higher levels of RSV and influenza infections on top of the ongoing COVID-19 pandemic. Giving people the ability to test for all three at home will improve the ability of healthcare systems to manage these infections in a timely manner. This is a welcome addition to our ViraxClear line of tests.
Plenty of upside ahead! > Virax Biolabs shares are trading higher after the company announced the distribution of a RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit has been launched in markets accepting the CE mark, such as the European Union.
VRAX
Cramer > When asked about Tellurian Inc. (NYSE: TELL), he said, "I am still in the buy, buy, buy."
Quad/Graphics (NYSE:QUAD) reported quarterly earnings of $0.32 per share. This is a 77.78 percent increase over earnings of $0.18 per share from the same period last year. The company reported $829.90 million in sales this quarter. This is a 17.53 percent increase over sales of $706.10 million the same period last year.
Excellent session! Closing bell > TORVF up 7.8% @ .971
Actinium shares are trading higher after the company announced the results from its pivotal Phase 3 SIERRA trial of iomab-b in patients with active relapsed or refractory acute myeloid leukemia met its primary endpoint of durable complete remission.
Congrats! More visibility, more investors accumulating each week.
$TORVF - Now on Stocktwits!
Volt Carbon Technologies > Stocktwits
https://stocktwits.com/symbol/TORVF
I wish I had bought .007 back in the day > James V- Bond is plugging away in the lab today. I hope Elon Musk buys TORVF. Better yet, any other established OEM EV companies. Regardless, all sorts of possibilities here for a multi-dollars upside.
Getting over the Buffalo Bills partying..... Some nice accumulation earlier. Let's go TORVF !
Diesel fuel shortage > Mansfield Energy issued the alert Friday stating there was a developing diesel fuel shortage in the southeastern region of the United States. The company speculated that the shortage could be generated from "poor pipeline shipping economies" and a historically low supply of diesel reserves.
"Poor pipeline shipping economics and historically low diesel inventories are combining to cause shortages in various markets throughout the Southeast," the company said. "These have been occurring sporadically, with areas like Tennessee seeing particularly acute challenges."
Diesel fuel shortage > Mansfield Energy issued the alert Friday stating there was a developing diesel fuel shortage in the southeastern region of the United States. The company speculated that the shortage could be generated from "poor pipeline shipping economies" and a historically low supply of diesel reserves.
"Poor pipeline shipping economics and historically low diesel inventories are combining to cause shortages in various markets throughout the Southeast," the company said. "These have been occurring sporadically, with areas like Tennessee seeing particularly acute challenges."
I just watched 30 minute video : Revenues!!!!! >" V-Bond also says that while small OEM battery development and contract work may help bring revenue, there’s also an opportunity in analyzing a battery and providing engineering expertise to other companies as a third party contractor."
PLUS any given OEM may buy this company >>>
Investors are forward looking! > $$$$$
Over the years, I have been in several OTC equities at this price level. I am looking at a potential of $2.00 to 3.00+ with TORVF. With positive fundamentals coming up, the sky is the limit. Remember, investors are forward looking. I mostly trade NYSE, and Nasdaq. TORVF will go Nasdaq in my opinion.
That's another positive catalyst among many others. Let's go TORVF.....
Plus the fact that there is not a lot of shares out there like most of the bloated pigs on the otc!
25 LIKES > You're burning the midnight lanterns with the solid research contributions. Nice post from October 3, 2022.
Definitely dino! Enjoy the weekend!
Very nice work CJ..... Some folks coming up with nice due diligence.
TORVF is definitely a world class equity. November is going to be amazing!
$TORVF - Volt Carbon Technologies Trades on 10 Exchanges!
If you are only looking at the OTC volume and trade book, then you are missing the trading activity happening on NINE other exchanges.
See my post here about Volt Carbon doing over 24,000,000 in volume outside the USA and only doing 400,000 volume on the OTC the very same day
Hey CJ ! > Natural, flake graphite, from particular high-grade flake graphite ore bodies, is far more desirable and is on the verge of an explosion in demand.
This bodes well for TORVF.
Yes, being in TORVF @ the right time. Finally, an exciting upside run is happening.
.17 a share in October, 2020. > May break .17 again in upcoming sessions.
TORVF > momo/fomo/herd is in process! > $weet! > $$$$$.
TORVF is #8 on ihub breakout boards this morning.
TORVF IS A GREAT $$$$$ OPPORTUNITY.
Looks like shelf placement closes on Monday.